Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 16, 2019. The document serves as a transaction notification reporting insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). It does not contain operational updates, earnings reports, or strategic business commentary.
Key Financial Metrics
The filing does not provide company-level financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary Shares (25 pence each) and American Depositary Shares (ADSs).
- Transaction Price (Ordinary Shares): £15.5009 per share.
- Transaction Price (ADSs): $40.8259 per ADS.
- Transaction Volume: Varied by individual executive, ranging from 0.001 shares to 3,072.811 shares.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records the acquisition of shares by executives following the re-investment of dividends paid on April 11, 2019.
Guidance, Outlook, and Risks
The filing contains no management guidance, future outlook, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of compliance with insider trading reporting requirements.
Investor Verification Checklist
- Verify that the reported share acquisitions were executed via dividend re-investment plans as stated.
- Confirm the transaction dates (April 12 and April 15, 2019) align with the dividend payment date of April 11, 2019.
- Check the London Stock Exchange (XLON) and New York Stock Exchange (XNYS) records for the reported share prices (£15.5009 and $40.8259).
- Ensure the list of PDMRs and PCAs matches the company's current executive roster.